Novavax, Inc.
NVAX Healthcare Biotechnology
Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 148.5%, free cash flow grew 43.0% and total debt rose 31.5%, each against the same quarter a year earlier.
Follow NVAX
Novavax, Inc. (NVAX) EV/Sales
As of 16 October 2026, Novavax, Inc. (NVAX) trades at a EV/Sales of 3.4×. Over the past ten years it has ranged from −0.4× (March 2023) to 210× (June 2020); the current reading is higher than 38% of that period. That is below the Biotechnology industry median of 9.2× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.5× | (30.33%) |
| FY2024 | 0.8× | 387.31% |
| FY2023 | 0.2× | — |
| FY2022 | −0.2× | — |
| FY2021 | 8.2× | (34.44%) |
| FY2020 | 12.6× | (29.96%) |
| FY2019 | 17.9× | (31.40%) |
| FY2018 | 26.1× | 59.01% |
| FY2017 | 16.4× | (36.00%) |
| FY2016 | 25.7× | (51.86%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.7× | 94.80% |
| Mar 2026 | 1.4× | 166.04% |
| Dec 2025 | 0.5× | (36.58%) |
| Sep 2025 | 0.8× | 43.68% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| PHVS Pharvaris N.V. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | 1.1× |
| NVAX Novavax, Inc. | 3.4× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| VCEL Vericel Corporation compare | 6.2× |
| VRDN Viridian Therapeutics, Inc. compare | 18.6× |
| IMNM Immunome, Inc. compare | 107× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)